Adding naltrexone–bupropion extended‑release to sleeve gastrectomy to improve weight loss
Official title: Improving Efficacity of Sleeve Gastrectomy With Naltrexone/Bupropion Extended-release Tablet - A Randomized Controlled Trial
Run by Laval University · NCT06620562 · Data updated 2026-11-12
This trial will test whether taking naltrexone–bupropion extended‑release after sleeve gastrectomy helps adults with obesity lose more weight and improve related health problems.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 108 (estimated) |
| Sponsor | Laval University Academic / other |
| Locations | 1 site (Québec, Quebec) |
| Status | Recruiting |
| Started | June 4, 2025 |
| Main results expected | June 2028 |
| Study ends | August 2028 |
| Registry record updated | August 8, 2025 |
| Trial ID | NCT06620562 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults scheduled for primary sleeve gastrectomy with BMI ≥30 kg/m2 plus an obesity‑related comorbidity or BMI ≥35 kg/m2 without comorbidities who can start medication one month after surgery and commit to 24 months of follow‑up are ideal candidates.
✕Probably not a fit
Patients with contraindications such as chronic opioid use, seizure disorder, current or past bulimia/anorexia, pregnancy or planned pregnancy, end‑stage liver or kidney disease, use of interacting drugs, or those undergoing revisional bariatric surgery are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, double‑blind trial will assign adults undergoing primary sleeve gastrectomy 1:1 to naltrexone–bupropion extended‑release or a matching placebo starting one month after surgery. The medication will be titrated progressively and continued for 24 months, and both groups will receive standardized behavioral and nutritional support. Primary outcomes are excess weight loss at 12 and 24 months and the proportion of patients achieving EWL >50%, with secondary measures including comorbidity resolution and changes in eating behaviors. The study is conducted at Laval University in Québec, Canada.
Why it matters
Potential benefit: If successful, adding naltrexone–bupropion could help post‑sleeve patients lose more excess weight, increase the chance of reaching clinically meaningful weight loss, and improve obesity‑related comorbidities and eating behaviors.
How similar studies have gone: Naltrexone–bupropion has proven effective for weight loss in non‑surgical populations, but its routine use after sleeve gastrectomy remains relatively untested with limited prior data.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * MBI above 30 kg/m2 with obesity-related comorbidity or above 35 kg/m2 without associated comorbidities. Exclusion Criteria: * Revisional or reoperative surgery * Pregnancy or planned pregnancy in the next 24 months * Simultaneous use of other weight loss medication * Uncontrolled hypertension * Chronic opioid use or opiate agonist (e.g., methadone) or partial agonists (e.g., buprenorphine) use, or acute opiate withdrawal. * Use of other bupropion-containing products * Concomitant administration of monoamine oxidase inhibitors. * End-stage liver or kidney disease * Concomitant use of CYP2B6 inhibitors (ticlopidine or clopidogrel) * Concomitant administration of the antipsychotic thioridazine * Seizure disorder or a history of seizures * Cardiac pacemaker * Current or prior diagnosis of bulimia or anorexia nervosa
Where it's running
-
Criucpq-Ul
Québec, Quebec, Canada Recruiting
Study contacts
- Study coordinator: Mélanie Nadeau
- Email: melanie.nadeau@criucpq.ulaval.ca
- Phone: 4186568711
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Endoscopic treatment for overweight and mild obesity using Orbera365
This study is testing whether the Orbera365 intragastric balloon can help people who are overweight or mildly obese lose weight over a year.
-
Using a new endoscopy technique for bariatric patients
This study is testing a new, less invasive endoscopy method for bariatric patients to see if it can improve safety and reduce costs when checking for stomach and digestive issues.
-
Endoscopic Antral Myotomy for Weight Loss
This study is testing a new weight loss procedure called Pylorus Sparing Antral Myotomy to see if it helps people with obesity lose weight safely and effectively on its own.
-
Improving outcomes for patients with failed sleeve gastrectomy using a new surgical approach
This study is testing a new type of surgery called SADI-S to see if it can help people who didn't have success with their previous sleeve gastrectomy lose weight and improve their health.
-
Ocular Changes in People Using Tirzepatide or Semaglutide
This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.
-
Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.